Early, integrated evidence planning that incorporates real‑world evidence (RWE) alongside clinical development is critical to meeting the needs of regulators, payers, physicians, and patients and avoiding costly evidence gaps later in development.

By introducing an Integrated Evidence Generation Plan (IEGP) by Phase 2, organizations can use RWE to inform trial design, regulatory strategy, and commercial positioning—ensuring evidence is ready when it has the greatest impact. Ultimately, treating RWE as a core, lifecycle‑wide component of evidence strategy enables stronger value narratives, faster market access, and better outcomes for patients.

Webinar attendees will:

• Learn how investing in an IEGP early reduces late‑stage evidence gaps and launch risk
• Explore how RWE can be strategically used across the product lifecycle to inform trial design, support regulatory decisions, and build compelling value narratives for payers, physicians, and patients